Demant reported strong Q4 22 results. Growth was driven by Hearing Healthcare, but partly offset by weaker Communications. Notably, despite difficult market conditions, the firm managed to report healthy results/organic growth. Moreover, the firm announced the launch of a new flagship hearing aid – which could be the most-important re-rating catalyst for Demant. Overall, the stock is worth a go at current levels.
07 Feb 2023
Strong Q4 + promising takeaways
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q4 + promising takeaways
- Published:
07 Feb 2023 -
Author:
Anas PATEL -
Pages:
3
Demant reported strong Q4 22 results. Growth was driven by Hearing Healthcare, but partly offset by weaker Communications. Notably, despite difficult market conditions, the firm managed to report healthy results/organic growth. Moreover, the firm announced the launch of a new flagship hearing aid – which could be the most-important re-rating catalyst for Demant. Overall, the stock is worth a go at current levels.